1. Home
  2. MIRM vs NHI Comparison

MIRM vs NHI Comparison

Compare MIRM & NHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • NHI
  • Stock Information
  • Founded
  • MIRM 2018
  • NHI 1991
  • Country
  • MIRM United States
  • NHI United States
  • Employees
  • MIRM N/A
  • NHI N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • NHI Real Estate Investment Trusts
  • Sector
  • MIRM Health Care
  • NHI Real Estate
  • Exchange
  • MIRM Nasdaq
  • NHI Nasdaq
  • Market Cap
  • MIRM 3.8B
  • NHI 3.7B
  • IPO Year
  • MIRM 2019
  • NHI 1991
  • Fundamental
  • Price
  • MIRM $69.89
  • NHI $73.60
  • Analyst Decision
  • MIRM Strong Buy
  • NHI Buy
  • Analyst Count
  • MIRM 11
  • NHI 4
  • Target Price
  • MIRM $79.00
  • NHI $82.75
  • AVG Volume (30 Days)
  • MIRM 580.7K
  • NHI 190.9K
  • Earning Date
  • MIRM 11-04-2025
  • NHI 11-06-2025
  • Dividend Yield
  • MIRM N/A
  • NHI 4.90%
  • EPS Growth
  • MIRM N/A
  • NHI 6.78
  • EPS
  • MIRM N/A
  • NHI 3.14
  • Revenue
  • MIRM $429,161,000.00
  • NHI $350,596,000.00
  • Revenue This Year
  • MIRM $53.14
  • NHI $4.68
  • Revenue Next Year
  • MIRM $19.83
  • NHI $10.60
  • P/E Ratio
  • MIRM N/A
  • NHI $23.46
  • Revenue Growth
  • MIRM 62.33
  • NHI 7.21
  • 52 Week Low
  • MIRM $36.88
  • NHI $65.13
  • 52 Week High
  • MIRM $78.55
  • NHI $82.32
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 43.37
  • NHI 39.50
  • Support Level
  • MIRM $68.34
  • NHI $74.61
  • Resistance Level
  • MIRM $71.86
  • NHI $76.05
  • Average True Range (ATR)
  • MIRM 2.36
  • NHI 1.69
  • MACD
  • MIRM -0.43
  • NHI -0.00
  • Stochastic Oscillator
  • MIRM 28.92
  • NHI 41.75

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About NHI National Health Investors Inc.

National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments, i.e., Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates maximum revenue, consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived in the form of rental income, mortgage and other notes receivable interest income, and resident fees and services.

Share on Social Networks: